

# Importance of Copay Assistance In Patient Affordability of Prescription Drugs

*Carl Schmid*  
*Executive Director*  
*HIV+Hepatitis Policy Institute*


*National Consumers League*  
*May 17, 2022*

**HIV+HEP**  

---

**POLICY INSTITUTE**


# Personal Healthcare Spending – 2019



Source: CMS National Health Expenditure Data, NHE 2019.

# Increasing Deductibles

Median QHP Deductibles – Silver Level



The PY22 silver plan median deductible is \$5,155, which is an increase of 6% from PY21 and 23% from PY18.

Source: <https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2022QHPPremiumsChoiceReport.pdf>

# Patient Affordability Study

- ▶ **About a third (32%) of single-person households with private insurance in 2019 could not pay a \$2,000 bill, and half (51%) could not pay a \$6,000 bill.**
- ▶ **Over 40% of multi-person households can't cover a mid-range employer family plan deductible of \$4,000, and 61% don't have enough to cover a high-range deductible.**
- ▶ **With an average out-of-pocket maximum for single coverage of \$4,272 in 2021 the study concludes: “Most households do not have enough liquid assets to meet the typical out-of-pocket maximum.”**

Gregory Young, Matthew Rae, Gary Claxton, Emma Wager, and Krutika Amin, Peterson-KFF Health System Tracker (Mar. 10, 2022), <https://www.healthsystemtracker.org/brief/many-households-do-not-have-enough-money-to-pay-cost-sharing-in-typical-private-health-plans/>

# Silver Plans: Copay vs Coinsurance (FFE & CA 2022)

## ▶ Preferred:

- 67% of plans use copayments (Average \$99)
- 33% of plans use coinsurance (Average 37%)

## ▶ Non-preferred:

- 24% of plans use copayments (Average \$159)
- 76% of plans use coinsurance (Average 45%)

## ▶ Specialty:

- 7% of plans use copayments (Average \$493)
- 93% of plans use coinsurance (Average 44%)

Source: Avalere PlanScape®, a proprietary analysis of exchange plan

# Patient Cost-Sharing for Drugs

Aggregate patient out-of-pocket cost for medicines dispensed in retail and non-retail settings, US\$Bn




Source: IQVIA Xponent, IQVIA LAAD Sample Claims Data, Dec 2021; IQVIA Institute, Mar 2022; CMS National Health Expenditures, Dec 2020.

Notes: Retail OOP based on LAAD sample prescription data, grossed up to NPA adjusted prescriptions normalizing for 90-day prescription dispensing. Non-retail estimates based on CMS NHE for personal healthcare excluding retail prescription drugs. IQVIA estimates of non-retail drug (modified by estimates of rebates and offset by applying the estimated net cost of insurance and typical channel markups) with CMS PHC OOP % applied to those amounts.

Report: The Use of Medicines in the U.S.2022. IQVIA Institute for Human Data Science, April 2022

# Cost-Sharing and Rx Abandonment

14-day abandonment share of new-to-product prescriptions by final out-of-pocket cost in 2021, all payers, all products




Source: IQVIA National Prescription Audit: New to Brand, LAAD Sample Claims Data, Dec 2021.

Notes: New to product prescriptions are those where patients have not had a prescription for the specific brand or generic drug within the prior year. Pharmacies in the sample provide information on prescriptions which were prepared for dispensing and whether they were dispensed, with abandonment defined as the prescription in question not being dispensed to the patient within 14 days of the initial fill. Analyses on a sample of claims projected to national totals, where a similar analysis in prior reports were not projected and thus not comparable in terms of total abandoned new prescriptions.

Report: The Use of Medicines in the U.S.2022. IQVIA Institute for Human Data Science, April 2022

# Role of Copay Assistance

Patient Out-of-Pocket Costs for Retail Prescriptions in Aggregate and Value Offset by Coupons, \$Bn



**Sources:**

IQVIA National Prescription Audit, Formulary Impact Analyzer, Jan 2019.  
IQVIA Xponent, IQVIA LAAD Sample Claims Data, Dec 2021; IQVIA Institute, Mar 2022; CMS National Health Expenditures, Dec 2020.

**Reports:**

Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023. IQVIA, May 2019.  
Medicine Spending and Affordability in the United States – Understanding Patients’ Costs for Medicines. IQVIA, August 2020.  
The Use of Medicines in the U.S. – Spending and Usage Trends and Outlook to 2025. IQVIA, May 2021.  
The Use of Medicines in the U.S. 2022 – Usage and Spending Trends and Outlook to 2026. IQVIA, April 2022.

- ▶ **Among commercially-insured patients on branded medications, 14% of them used coupons to reduce their out-of-pocket costs in 2020 – IQVIA**
- ▶ **Now is not the time to reduce Copay Assistance**

# Thank you!

*Carl Schmid*

*Executive Director*

*HIV + Hepatitis Policy Institute*

*[cschmid@hivhep.org](mailto:cschmid@hivhep.org)*

Follow: @HIVHep

**HIV + HEP**

---

POLICY INSTITUTE